Clinical Trials

The Cutaneous Lymphoma Foundation provides information about clinical trials to help move new treatments forward. There may be clinical trials available that we are not aware of. To find additional trials, visit clinicaltrials.gov. Keep in mind that many sponsors of clinical trials cover transportation and other costs for patient participation so we encourage you to consider trials that may not be close to you. Clinical trials are grouped by countries and regions - please limit your search to these options - individual states will yield no results.

United States

Naloxone Hydrochloride Study for Relief of Pruritus/Itch (MW)

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL).

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study (MW)

To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR) - Midwest

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma

A phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA  

Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor (MW)

The purpose of this study is to better understand the use of Valchlor® in clinical practice. Other goals include describing the demographic and clinical characteristics of the disease and health outcomes of patients treated with Valchlor® .

A Dose-Ranging Study of IV BNZ-1 (MW)

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

Safety and Efficacy Study of a Dual Pi3k Delta/Gamma Inhibitor in T-Cell Lymphoma (MW)

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Naloxone Hydrochloride Study for Relief of Pruritus/Itch (NE)

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL).

Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor (NE)

The purpose of this study is to better understand the use of Valchlor® in clinical practice. Other goals include describing the demographic and clinical characteristics of the disease and health outcomes of patients treated with Valchlor® .

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study (NE)

Purpose: To evaluate the use of SGX301, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma

A phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA  

A Dose-Ranging Study of IV BNZ-1 (NE)

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

STUDY OF COBOMARSEN IN PATIENTS WITH MYCOSIS FUNGOIDES (SOLAR) - Northeast

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype.

Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor (SE)

The purpose of this study is to better understand the use of Valchlor® in clinical practice. Other goals include describing the demographic and clinical characteristics of the disease and health outcomes of patients treated with Valchlor® .